REGN vs XFOR
REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases. XFOR: A biopharmaceutical company developing mavorixafor, an oral CXCR4 antagonist, to treat rare hematology conditions like chronic neutropenia and WHIM syndrome.
Side-by-side fundamentals
| Metric | REGN | XFOR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $739.57 | $2.79 | |
| Market cap | $69.5B | $277M | |
| P/E as of 2026-10-08 | 18.28 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 6.61 | n/a | |
| Net margin FY2025, SEC XBRL | +31.4% | -225.6% | REGN higher |
| Operating margin FY2025, SEC XBRL | +24.9% | -247.4% | REGN higher |
| ROE FY2025, SEC XBRL | +14.4% | -42.5% | REGN higher |
| ROA FY2025, SEC XBRL | +11.1% | -27.3% | REGN higher |
| Debt / equity as of 2026-09-02 | 0.09 | 0.45 | REGN lower |
| Revenue growth (YoY) as of 2026-09-02 | +9.3% | -71.3% | REGN higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | n/a | |
| Dividend yield as of 2026-09-02 | +0.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-02 | 0.61 | 1.29 | |
| 1-year return as of 2026-10-08 close | +31.2% | -16.0% | REGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.